Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by US Bancorp DE

US Bancorp DE boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 22.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 115,238 shares of the medical equipment provider’s stock after buying an additional 21,097 shares during the period. US Bancorp DE owned approximately 0.06% of Zimmer Biomet worth $12,932,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Horizon Bancorp Inc. IN boosted its stake in Zimmer Biomet by 1,483.3% in the second quarter. Horizon Bancorp Inc. IN now owns 190 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 178 shares during the period. Clear Street Markets LLC acquired a new position in Zimmer Biomet in the fourth quarter worth approximately $27,000. OLD Point Trust & Financial Services N A purchased a new position in shares of Zimmer Biomet in the second quarter worth approximately $32,000. WealthPLAN Partners LLC purchased a new position in shares of Zimmer Biomet during the second quarter valued at $39,000. Finally, Dark Forest Capital Management LP acquired a new stake in shares of Zimmer Biomet during the first quarter worth approximately $35,000. Institutional investors and hedge funds own 87.48% of the company’s stock.

Zimmer Biomet Stock Down 0.2 %

Shares of NYSE:ZBH traded down $0.26 during trading hours on Friday, hitting $121.70. The company’s stock had a trading volume of 519,528 shares, compared to its average volume of 1,647,443. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.11 and a quick ratio of 0.99. The company has a market capitalization of $25.43 billion, a price-to-earnings ratio of 53.99, a P/E/G ratio of 2.22 and a beta of 1.03. The firm’s fifty day moving average price is $119.01 and its 200 day moving average price is $118.99. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $149.25.

Zimmer Biomet (NYSE:ZBHGet Free Report) last posted its earnings results on Tuesday, November 7th. The medical equipment provider reported $1.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.59 by $0.06. Zimmer Biomet had a net margin of 6.52% and a return on equity of 12.41%. The firm had revenue of $1.75 billion during the quarter, compared to analysts’ expectations of $1.75 billion. During the same period in the previous year, the business posted $1.58 EPS. The business’s revenue was up 5.0% compared to the same quarter last year. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.51 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Wednesday, December 27th will be given a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, December 26th. This represents a $0.96 annualized dividend and a yield of 0.79%. Zimmer Biomet’s dividend payout ratio is presently 42.48%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ZBH. JMP Securities decreased their target price on Zimmer Biomet from $160.00 to $140.00 and set a “market outperform” rating for the company in a research report on Monday, November 13th. Royal Bank of Canada increased their price objective on Zimmer Biomet from $134.00 to $140.00 and gave the stock an “outperform” rating in a research note on Friday, January 12th. StockNews.com initiated coverage on Zimmer Biomet in a report on Thursday, October 5th. They set a “buy” rating on the stock. Citigroup dropped their target price on Zimmer Biomet from $146.00 to $125.00 and set a “neutral” rating for the company in a research report on Monday, October 2nd. Finally, Evercore ISI lowered shares of Zimmer Biomet from an “outperform” rating to an “inline” rating and reduced their price objective for the stock from $135.00 to $125.00 in a research note on Thursday, January 4th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $137.60.

View Our Latest Analysis on ZBH

About Zimmer Biomet

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Recommended Stories

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.